Executive & Senior-Level
Biopharma Roles

CEO

Large Molecule CDMO

Head of Peptide Chemistry / Co-founder

Peptide Chemistry

VP of Neural AI

Brain Science / Neuroscience / BCI

Director / SD-VP of Formulations & Innovative Processes

Small Molecule Complex Formulations

VP of Global Audit Center

Biotech / Pharma MNC — Internal Audit

Head of Nucleic Acid Drug R&D

Nucleic Acid Therapeutics

Head of TCE

T-Cell Engagers

VP of Biostatistics

Biostatistics / Mathematics / Epidemiology

Medicinal Chemistry Expert

Metabolism

CSO / Associate Dean

CNS & Cardiovascular

Dean / Associate Dean — Chemical Drug Research Institute

Organic Synthesis

Biology VP

Large Molecule — Autoimmune

Biology Head

Autoimmune / Oncology

Biology CSO / VP / Director

Large Molecule — Oncology

Director of New Drug R&D

Small Molecule — Immuno-Oncology

Director of Antibody Discovery

Immuno-Oncology

Biology Head

CNS

CEO / CSO

CNS

CSO / VP / CTO

Metabolism & Weight Loss

Head of Process Development (PD)

Large Molecule

Head of Antibody Discovery & Engineering Platform

Antibody Platform

Head of Peptide Drug R&D

Peptide Drugs

CMO / Medical VP

Immuno-Oncology / Metabolism

CEO

CNS / Metabolism / CV / Oncology / Immunology

CGT Technology Expert

Cell & Gene Therapy — New Drug Screening

Medicinal Chemistry VP

ADC

Vice President of Strategy

Biopharma Strategy (Large & Small Molecule)

Beijing-based; 2–3M RMB annual compensation; reports to CEO; PhD in a pharmaceutical discipline; overseas background a plus.

Vice President of Medical Affairs

Solid Tumors / Hematologic Malignancies / Autoimmune Diseases (Beijing — A-share Listed Company)

Medical Director

Overseas Project Interface (Guangdong — A-share Listed Company, ~100B RMB Market Cap)

Senior Medical Director

Autoimmune Diseases (Beijing — HK Stock Exchange Listed Company)

(Sr.) Director, Pharma Partnering Transactions (BD&L)

Roche — Basel, Switzerland

Owns valuation, structuring, term-sheet negotiation, and closing for headline in- and out-licensing across Roche's pharma division.

Director, Business Development & Acquisitions (AI Drug Discovery)

AbbVie — South San Francisco, CA

Identifies and analyzes BD opportunities focused on AI-enabled drug-discovery platforms; reports into one of the most active dealmaking BD groups in big pharma.

Head, Business Development & Licensing — Pharmaceutical Sciences

Takeda — Cambridge, MA

Manages BD&L deal-flow for the pharm-sciences portfolio (CMC, manufacturing, drug-product platform deals); sits at the seam between BD and tech-ops.

Associate Director, Regulatory Strategy

Lundbeck — Deerfield, IL (CNS portfolio)

Public, banded comp: $175,000–$205,000 + 20% bonus. Supports regulatory strategy for Lundbeck's depression, Alzheimer's, and migraine pipeline.

Director, Regulatory Affairs — CMC

ICON plc — Multiple US locations / hybrid

Leads client CMC submissions across cell & gene therapy, ADCs, and bispecifics — positioned to capture the externalization wave from Big Pharma manufacturing consolidations.

Director, Global Regulatory Affairs (Oncology)

Protara Therapeutics — New York, NY / hybrid

Chief Scientific Officer (CSO)

ADC-focused innovative-drug subsidiary of a publicly listed company (Confidential)

Direct management of a 40+ person R&D organization; deep ADC R&D experience essential.

Head of Biologics Innovation Research Institute

Publicly listed pharma group — China

Leads a 100+ person biologics innovation research institute; reports to the parent company chief R&D officer.

ADC R&D Director / VP

Publicly listed oncology / immunotherapy company — Beijing, China

URGENT — hiring on a 60–90 day start timeline. Deep expertise in site-specific ADC conjugation chemistry is a hard requirement.

CEO — Single-Molecule Protein Sequencing / Nanopore Startup

Early-stage startup (national-level R&D grant) — Sichuan, China

Adjacent electrophysiology platform with existing products provides a near-term commercial revenue path. Strong preference for a technically literate CEO with overseas experience.

Stem Cell Expert — Tumor-Targeted Therapy / Immune Modulation

Biopharmaceutical company — Guizhou, China

RMB 2M+ annual salary + 20% equity. Equity-rich compensation reflects founding-team-style commitment expectation.

Director, Early-Stage R&D — Innovation Projects Department

Publicly listed oncology / immunotherapy company — Beijing, China

Cross-functional mandate spanning target ID, modality selection, and partnership / in-licensing — pipeline synergy with the ADC R&D VP search at the same listed group.